Nuvalent (NASDAQ:NUVL) 주식

NUVALENT INC-A

Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Bridgewater,,Nj,,Usa,-,August,23,,2022:,Bausch,Health,Us

Mid Cap

News

Movers

Trading Ideas

ASND

BLCO

EWTX

NUVL

POWL

지난주 연방준비제도(연준)가 금리를 50bp(베이시스 포인트) 인하하기로 결정하면서 기술, 건설, 산업, 기계 그리고 금융 부문 전반에 걸쳐 주가가 상승했다. 지난주 가장 좋은 실적을 보인 중형주 7종목은 다음과 같다. 여러분의 포트폴리오에 포함되어 있나요?

바우쉬 헬스와 엣지와이즈는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 15일-9월 21일)

Lucid

CRDO

GRFS

LCID

PRCT

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 루시드 그룹(NASDAQ:LCID)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 캐나다의 다양한 금융 옵션에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다. 

루시드 및 그리폴스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (8월 18일-8월 24일)

Nuvalent Inc

Press Releases

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Earnings

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Nuvalent to Participate in Upcoming March Investor Conferences

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

ADMA Biologics

Akero Therapeutics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Vaxcyte

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Comments

Nuvalent

뉴스

파트너 / 기고자

벤징가 글로벌